SCIPI for Prostate Cancer
(SCIPI Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a web-based program called SCIPI, designed to assist men with localized prostate cancer and their families. The program provides easy-to-understand information, tools for doctor communication, and social support. Researchers aim to determine if SCIPI can complement regular prostate cancer care and help patients feel more confident about their treatment choices while improving their quality of life. Men newly diagnosed with localized prostate cancer who can access the internet are encouraged to participate. Participants will either use the SCIPI program or continue with their usual care, and researchers will track their experiences over time. As an unphased trial, this study offers participants the chance to contribute to innovative research that could enhance prostate cancer care for future patients.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It focuses on a supportive care program and does not mention medication changes.
What prior data suggests that SCIPI is safe for prostate cancer patients?
Past studies on SCIPI, a web-based support program for prostate cancer patients, have shown no safety concerns. This program is not a medical treatment like a drug or surgery. Instead, it provides information and support to help patients make informed decisions about their care. As a digital tool, SCIPI avoids the risks associated with physical treatments. Participants use it to access information and connect with others, which is generally safe and well-tolerated. Research on this type of support program has reported no negative effects.12345
Why are researchers excited about this trial?
Researchers are excited about SCIPI for prostate cancer because it introduces a new way to support patients through a web-based program, enhancing their care experience via Epic MyChart. Unlike traditional treatments that focus solely on medical interventions like surgery, radiation, or hormone therapy, SCIPI aims to improve overall patient well-being by integrating supportive care directly into their usual healthcare routine. This innovative approach may help patients manage symptoms and improve their quality of life, making treatment a more holistic experience.
What evidence suggests that SCIPI is effective for prostate cancer?
Research has shown that online programs like SCIPI, which participants in this trial may receive, can help men with localized prostate cancer. In similar programs, participants developed better coping skills and experienced an improved quality of life. One study found that men using a similar program felt more confident about their treatment choices. This suggests SCIPI might help patients feel more supported and informed. Although SCIPI is still under study in this trial, early results appear promising for enhancing patient care and decision-making.16789
Who Is on the Research Team?
Lixin Song, PhD
Principal Investigator
The University of Texas Health Science Center at San Antonio
Are You a Good Fit for This Trial?
This trial is for men newly diagnosed with localized prostate cancer. It aims to see if a web-based program, SCIPI, can be integrated into clinical care and if it helps patients feel more confident in their treatment decisions and improves their quality of life.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Baseline Assessment
Participants provide informed consent and complete the baseline assessment (T1)
Intervention
Participants are randomly assigned to either the SCIPI intervention or usual care
Follow-up
Participants are monitored for decision satisfaction, quality of life, and other outcomes
What Are the Treatments Tested in This Trial?
Interventions
- SCIPI
Trial Overview
The study is testing the Support, Communication, and Information Program for Prostate Cancer - Interactive (SCIPI), which provides information, decision-making tools, and social support. Participants will either use SCIPI or receive usual care to compare outcomes.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Active Control
Participants will receive SCIPI, a web-based supportive care program delivered through the Epic MyChart system, in addition to usual care.
Participants will receive usual care provided at their study site.
Find a Clinic Near You
Who Is Running the Clinical Trial?
The University of Texas Health Science Center at San Antonio
Lead Sponsor
University of California, San Diego
Collaborator
University of Kansas Medical Center
Collaborator
University of North Carolina, Chapel Hill
Collaborator
Citations
Study Details | NCT07280897 | SCIPI Implementation and ...
SCIPI provides men with localized prostate cancer and their families with easy-to-understand information, tools to prepare for discussions with their doctors, ...
Lymphocyte-sparing pelvic radiotherapy for prostate cancer
For prostate bed plans, the V40Gy for Ls-BM, Il-BM, and Lp-BM was decreased by 25 %, 59 %, 56 %, respectively. For Wp-BM, the V10Gy, V20Gy, and Dmean have been ...
Feasibility, acceptability, and preliminary efficacy of a ...
Our overall findings are similar to a CBSM intervention for men with early-stage prostate cancer in which participants demonstrated significant ...
Development of an effective predictive screening tool for ...
When predicting high risk cancer in the validation cohort, ClarityDX Prostate showed 95% sensitivity, 35% specificity, 54% positive predictive ...
Image-guided Intensity-modulated Radiotherapy for ...
Results: After a median observation time of 26 (range=15-48) months, the 3-year biochemical failure-free survival was 96.5% [95% confidence interval (CI)=89%-98 ...
Treatment Decision Support for Men with Prostate Cancer and ...
We developed a tablet-based interactive knowledge model of PC to provide personalized and patient-centered information on treatment and outcomes for patients ...
Artificial intelligence for diagnosis and Gleason grading of ...
Gleason grading of biopsies yields important prognostic information for prostate cancer patients and is a key element for treatment planning.
Original Article Impact of target volume and dose concepts ...
Data of prostate cancer patients receiving SBRT for spine BoM between 2010 and 2024 at 19 European cancer centers were retrospectively collected. Treatment ...
Lymphocyte-sparing pelvic radiotherapy for prostate cancer
The aim of this study is to evaluate the feasibility of lymphocyte-rich organs at risk (LOAR) sparing in pelvic irradiation for localized prostate cancer.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.